1 Global Human Rabies Immune Globulin (HRIG) Market Size (Value) and CAGR (2024-2033)
In 2024, the global Human Rabies Immune Globulin (HRIG) market was valued at USD 600.85 million, with a CAGR of 2.5% from 2024 to 2033.
Human Rabies Immune Globulin (HRIG) is a rabies immunoglobulin obtained by collecting the plasma of a person immunized with a human rabies vaccine and using low-temperature ethanol protein separation or other approved separation and manufacturing processes.
Figure Global Human Rabies Immune Globulin (HRIG) Market Size (M USD) and CAGR 2024-2033
2 Human Rabies Immune Globulin (HRIG) Market Drivers
The Human Rabies Immune Globulin (HRIG) market is experiencing significant growth driven by several key factors. One of the primary drivers is the increasing awareness of the dangers of rabies and the importance of immediate post-exposure prophylaxis (PEP). The World Health Organization (WHO) recommends the use of HRIG for individuals exposed to rabies, emphasizing its role in providing rapid protection against the virus. This has led to higher adoption rates of HRIG in both developed and developing countries.
Another significant driver is the rising number of pet ownership globally. With more households owning pets, the risk of rabies exposure through animal bites and scratches has increased. According to recent data, approximately 33% of households worldwide own pets, with a significant number of these being dogs and cats. The increase in pet ownership has led to a higher demand for HRIG, as pet owners are more likely to seek immediate medical attention for potential rabies exposure.
Additionally, advancements in healthcare infrastructure and the availability of improved healthcare services have contributed to the growth of the HRIG market. Countries with robust healthcare systems are better equipped to diagnose and treat rabies exposures, leading to increased use of HRIG. The development of new and more effective HRIG formulations has also played a role in driving market growth. For example, Grifols’ HyperRAB® 300 IU/ml formulation offers a higher concentration of antibodies, requiring fewer injections and providing better protection.
3 Human Rabies Immune Globulin (HRIG) Market Restraints
Despite the growth drivers, the HRIG market faces several challenges and restraints. One of the primary challenges is the limited availability of high-quality rabies immune plasma, which is the main raw material for HRIG production. The production of HRIG requires plasma donors to be immunized with the rabies vaccine, and the process is both time-consuming and expensive. This has led to supply shortages and increased production costs, making HRIG products more expensive and less accessible to patients in low-income regions.
Another significant restraint is the high cost of HRIG production. The process involves multiple stages, including plasma collection, purification, and virus inactivation, all of which require significant investment in technology and labor. The high cost of production translates to higher prices for patients, which can be a barrier to its widespread use.
4 Global Human Rabies Immune Globulin (HRIG) Market Size by Type in 2024
The 100 IU/ml HRIG type is the most widely used and holds the largest market share. In 2024, this type is expected to have a market value of $326.04 million, accounting for approximately 54.3% of the total HRIG market. This type is characterized by its balanced concentration and cost-effectiveness, making it suitable for a broad range of applications, particularly for Category II exposures, such as minor scratches or abrasions without bleeding. Its widespread use and accessibility contribute significantly to its market dominance. The growth of the 100 IU/ml HRIG market is driven by its versatility and the increasing demand for cost-effective solutions in rabies prevention.
The 150 IU/ml HRIG type is the second most significant segment, with a projected market value of $165.17 million in 2024, representing about 27.5% of the total market. This type offers a higher concentration of antibodies compared to the 100 IU/ml type, making it more effective in neutralizing the rabies virus in severe exposure cases. It is primarily used for Category III exposures, such as severe bites or scratches that penetrate the skin. The market for 150 IU/ml HRIG is growing due to its increased efficacy in high-risk scenarios and the rising awareness of the importance of effective post-exposure prophylaxis.
The 300 IU/ml HRIG type, while the smallest segment, is growing rapidly. In 2024, it is expected to have a market value of $109.65 million, accounting for approximately 18.2% of the total HRIG market. This high-concentration type provides the most potent protection against rabies, making it ideal for the most severe exposure cases, such as multiple bites or scratches, or when the exposure involves mucous membranes or broken skin. The market for 300 IU/ml HRIG is driven by the increasing demand for more potent treatments in high-risk scenarios, particularly in regions with high incidences of rabies.
Table Global Human Rabies Immune Globulin (HRIG) Market Size by Type in 2024
Type | Market Size (M USD) 2024 |
100 IU/ml | 326.04 |
150 IU/ml | 165.17 |
300 IU/ml | 109.65 |
5 Global Human Rabies Immune Globulin (HRIG) Market Size by Application in 2024
In 2024, the market value for HRIG used in Category II exposures is projected to be $29.65 million. This category includes minor wounds such as superficial scratches or abrasions without bleeding. These cases typically require less intensive treatment compared to Category III exposures. The market for HRIG in Category II exposures is driven by the need for immediate protection against rabies in cases where the risk is moderate. Despite the relatively lower market share, this segment is essential for ensuring broad coverage and accessibility of HRIG for minor exposure cases.
The market value for HRIG used in Category III exposures is projected to be $571.21 million in 2024. This category includes more severe exposures such as single or multiple transdermal bites or scratches, contamination of mucous membranes or broken skin with saliva from animal licks, and exposures due to direct contact with bats. These cases pose a higher risk of rabies infection and require immediate and effective treatment. The market for HRIG in Category III exposures is significantly larger due to the higher concentration of antibodies needed to neutralize the virus in severe cases.
Table Global Human Rabies Immune Globulin (HRIG) Market Size by Application in 2024
Application | Market Size (M USD) 2024 |
Category II Exposure | 29.65 |
Category III Exposure | 571.21 |
6 Global Human Rabies Immune Globulin (HRIG) Market Size by Region in 2024
The North American market for HRIG is projected to be valued at $161.34 million in 2024. This region includes the United States and Canada, where healthcare infrastructure is robust, and awareness of rabies prevention is high. The market in North America is driven by the need for effective post-exposure prophylaxis, particularly in areas with high incidences of rabies. The region also benefits from advanced healthcare facilities and the availability of high-quality HRIG products. The growth of the HRIG market in North America is influenced by increasing pet ownership and the need for effective rabies prevention measures.
The China market for HRIG is projected to be valued at $278.60 million in 2024. China is a major player in the global HRIG market, driven by its large population and increasing healthcare investments. The market in China is characterized by a high demand for HRIG due to the significant number of rabies cases reported annually. The growth of the HRIG market in China is also influenced by the government’s focus on improving healthcare infrastructure and increasing awareness of rabies prevention. Additionally, China’s large manufacturing base for blood products contributes to the availability of HRIG products in the region.
The Indian market for HRIG is projected to be valued at $26.34 million in 2024. India is another significant market for HRIG, driven by its large population and increasing awareness of rabies prevention. The market in India is characterized by a high demand for cost-effective HRIG products, particularly in rural areas where healthcare infrastructure is less developed. The growth of the HRIG market in India is influenced by the increasing number of pet ownership and the need for effective rabies prevention measures. Additionally, the Indian government’s focus on improving healthcare infrastructure and increasing awareness of rabies prevention is expected to drive market growth.
Figure Global Human Rabies Immune Globulin (HRIG) Market Size by Region in 2024
7 Major Players in Global Human Rabies Immune Globulin (HRIG) Market
7.1 Grifols
Company Profile:
Grifols is a global healthcare company with over 75 years of experience, dedicated to improving the health and well-being of people around the world. Established in 1909, Grifols is headquartered in the United States and has a network of over 180 plasma donation centers. The company is a leading producer of plasma-derived medicines used to treat rare, chronic, and life-threatening conditions. Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion.
Business Overview:
Grifols’ business encompasses the production of essential plasma-derived medicines for patients and the provision of tools, information, and services to hospitals and healthcare professionals. The company’s Hospital Division provides intravenous therapies, clinical nutrition products, and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.
Product Introduction:
Grifols’ HRIG product, HyperRAB (300 IU/ml), is the first and only high-potency HRIG that enables the delivery of more of the total dose per mL at the wound site. HyperRAB offers half the volume of medication administered in a total dose, potentially resulting in fewer injections. It also provides twice the concentration of rabies antibodies per mL at the wound site, regardless of the wound size. The product comes in three vial sizes (1 mL, 3 mL, and 5 mL) and has a three-year shelf life with room temperature storage for up to six months.
Recent Financial Data:
In the most recent year, Grifols reported sales of 154 liters of HRIG, with a market value of $108.26 million.
7.2 CSL Behring
Company Profile:
CSL Behring is a global leader in biotherapeutics, focused on meeting the needs of patients by using the latest technologies. Established in 2000, the company is headquartered in Germany and operates primarily in Europe and Asia. CSL Behring discovers, develops, and delivers innovative therapies in the areas of immunology, hematology, cardiovascular and metabolism, respiratory, and transplantation.
Business Overview:
CSL Behring uses three strategic scientific platforms—plasma fractionation, recombinant protein technology, and cell and gene therapy—to support continuous innovation. The company aims to improve the way products address unmet medical needs and help patients live fulfilling lives. CSL Behring’s extensive portfolio includes a variety of plasma-derived and recombinant products used in critical care settings.
Product Introduction:
CSL Behring’s HRIG product, Berirab®, is a solution for injection for intramuscular use. It contains human rabies immunoglobulin and is used for the prevention of rabies after suspected exposure. Berirab® is indicated for scratch or bite wounds or other injuries caused by animals suspected of having rabies. The product must always be given in combination with a rabies vaccine and adheres to national and/or WHO recommendations for rabies protection.
Recent Financial Data:
In the most recent year, CSL Behring reported sales of 1404 liters of HRIG, with a market value of $76.01 million.
7.3 Kamada
Company Profile:
Kamada Ltd. is a commercial-stage plasma-derived biopharmaceutical company focused on orphan indications. Established in 1990 and headquartered in Israel, Kamada uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma. The company produces Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived immune globulins.
Business Overview:
Kamada’s business is centered on the development and commercialization of plasma-derived products for orphan indications. The company’s KamRab product has been approved by the FDA and is marketed in the United States under the brand name KEDRAB® through a strategic partnership with Kedrion SpA. Kamada’s focus on orphan indications and its commitment to innovation have positioned it as a key player in the HRIG market.
Product Introduction:
Kamada’s HRIG product, KamRab, is indicated for passive, transient post-exposure prevention of rabies infection when given immediately to individuals in cases of contact with rabid or possibly rabid animals. KamRab contains human rabies immunoglobulin at a concentration of 150 IU/ml and is administered intramuscularly. The product is designed to provide rapid protection against rabies in high-risk exposure cases.
Recent Financial Data:
In the most recent year, Kamada reported sales of 137 liters of HRIG, with a market value of $51.93 million.